Document is current
Any future updates will be listed below
-
Authors
Wieczorek, Aleksandra https://orcid.org/0000-0001-6750-2628
Śladowska, Katarzyna https://orcid.org/0000-0002-6633-0999
Lode, Holger N. https://orcid.org/0000-0002-1201-208X
-
Funding
Funding for this research was provided by:
Recordati Rare Diseases
- License Information
-
More Information
Article History
Accepted: 13 May 2025
First Online: 3 June 2025
Declarations
:
: Editorial support by mXm Medical Communications and data extraction by Centrum HTA were funded by Recordati Rare Diseases.
: AW has provided expert opinion to EUSA Pharma/Recordati Rare Diseases and participated in advisory boards organised by EUSA Pharma/Recordati Rare Diseases. KŚ has acted as consultant and participated in advisory boards organised by EUSA Pharma/Recordati Rare Diseases. HL has acted as consultant for Apeiron and EUSA Pharma for the clinical development of dinutuximab beta and participated in advisory boards organised by EUSA Pharma.
: Not applicable.
: Not applicable.
: Not applicable.
: Data and materials are available upon request from the corresponding author.
: Not applicable
: AW conceived and designed the analysis. AW and HL supervised the project. AW and KŚ collected and extracted the data and performed the analysis. All authors contributed data or analysis tools, wrote the manuscript, and reviewed and approved the final version of the manuscript.
